ArticleCancers2023

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations.

Soojin Jun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.